Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Levetiracetam is an effective add-on epilepsy treatment

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7194 p521-527
20 April 2002

This article
Reprint
Photocopy


News summary

Related websites
Drug and Therapeutics Bulletin(more)


Levetiracetam is an effective add-on epilepsy treatment

LEVETIRACETAM (Keppra) is an effective adjunctive treatment for adults with partial epilepsy that is not controlled with standard antiepileptic drugs, according to the Drug and Therapeutics Bulletin.

The bulletin says that evidence from mainly short-term studies indicates that levetiracetam at least halves seizure frequency in about 40 per cent of patients and around one in 16 patients treated with the drug becomes seizure-free. In these terms, "levetiracetam appears at least as effective as, or better than, currently available add-on anti-epileptic drugs," it says. However, the bulletin cautions that assessing the place of levetiracetam in treatment is hampered by a lack of comparative controlled trials of anti-epileptic drugs and that such studies are urgently needed.

In addition, levetiracetam was found to be generally well-tolerated and have no pharmacological interactions with other antiepileptics, oral contraceptives, warfarin or digoxin (2002;40:30).

The bulletin also reviews management of infective endocarditis (ibid, p26).

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20006551

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.